Close Menu

OICR

Recently, Mao Mao, a research fellow at Pfizer Oncology Research who is working on several different cancer sequencing projects, spoke to In Sequence about the company's use of sequencing in drug development and the hurdles that still remain in implementing the technology in pharmaceutical research.

Canada's research institutions should launch a new prostate cancer sequencing project within the International Cancer Genome Consortium, and promote the value of its data to Canadian researchers, a 22-member alliance recommended today in its Pan-Canadian Cancer Research Strategy.

The Toronto-based institute has made investments in a multiplexed biomarker identification tool company and a planned spin-off that is developing a microchip-based rapid diagnostic system.

OICR is completing a new lab for its Medicinal Chemistry Platform, and has moved into a new server room for its Informatics and Bio-Computing Platform that allows the institute to double its data storage capacity from 1.5 to 3 petabytes.

A portion of funding that the Ontario Institute for Cancer Research is providing will go toward genomics and biomarker research programs.

The institute intends to add more than 40 people at its hub in Toronto and step up its Intellectual Property Development and Commercialization program, which awards pre-commercial "valley of death" funding toward commercializing intellectual property based at least partially on research carried out in Ontario.

The agreement, under which Life Technologies will co-market Agilent's SureSelect Target Enrichment System with the Applied Biosystems SOLiD sequencer, follows a similar deal that Agilent signed with Illumina in April.

The company said it currently has more than a dozen customers, including Pfizer, the Flanders Institute for Biotechnology, Duke University, Brigham & Women's Hospital, the HudsonAlpha Institute for Biotechnology, and the Ontario Institute for Cancer Research, in addition to the Institute for Systems Biology and the Broad Institute, which Complete announced previously. It has also sequenced a single human genome for Harvard's Personal Genome Project.

The announcement follows two installations of the company's single-molecule sequencing system during the second quarter, one at the Massachusetts General Hospital Cancer Center and one at an undisclosed biotechnology company in the Northeast.

The company's shares were up 40 percent in mid-morning trade on the Nasdaq exchange.

Pages

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.